PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 41 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,337,600 | -39.6% | 320,000 | 0.0% | 0.10% | -35.6% |
| Q2 2023 | $8,838,400 | +54.5% | 320,000 | +16.4% | 0.15% | -50.0% |
| Q4 2017 | $5,720,000 | +158.9% | 275,000 | +120.0% | 0.30% | +138.4% |
| Q3 2017 | $2,209,000 | +56.2% | 125,000 | 0.0% | 0.12% | +42.0% |
| Q2 2017 | $1,414,000 | – | 125,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 3,446,874 | $154,696,000 | 18.62% |
| Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 | $109,919,000 | 11.24% |
| BVF INC/IL | 3,754,095 | $168,484,000 | 6.32% |
| Tri Locum Partners LP | 341,650 | $15,333,000 | 5.02% |
| Twin Lakes Capital Management, LLC | 143,440 | $6,438,000 | 3.58% |
| COMMODORE CAPITAL LP | 210,600 | $9,452,000 | 3.29% |
| Altium Capital Management LP | 282,445 | $12,676,000 | 2.94% |
| Pinz Capital Management, LP | 196,000 | $8,796,000 | 2.65% |
| Opaleye Management Inc. | 330,222 | $14,820,000 | 2.46% |
| RTW INVESTMENTS, LP | 3,507,390 | $157,412,000 | 2.38% |